Hanmi Science Co., Ltd. (KRX:008930)
South Korea
· Delayed Price · Currency is KRW 38,100
-400 (-1.04%)
Apr 29, 2026, 3:00 PM KST
Hanmi Science Revenue
In the year 2025, Hanmi Science had annual revenue of 1.36T KRW with 5.73% growth. Hanmi Science had revenue of 285.67B in the quarter ending December 31, 2025, with 5.17% growth.
Revenue
1,356.96B
Revenue Growth
+5.73%
P/S Ratio
1.92
Revenue / Employee
2.85B
Employees
476
Market Cap
2,606.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1,356.96B | 73.53B | 5.73% |
| Dec 31, 2024 | 1,283.43B | 35.53B | 2.85% |
| Dec 31, 2023 | 1,247.91B | 201.85B | 19.30% |
| Dec 31, 2022 | 1,046.05B | 95.89B | 10.09% |
| Dec 31, 2021 | 950.16B | 92.78B | 10.82% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,814.00B |
| Celltrion | 4,162.50B |
| ALTEOGEN | 215.86B |
| Samsung Epis Holdings | 1,510.14B |
| SK bioscience | 651.37B |
| PharmaResearch | 536.29B |
| Hugel | 425.11B |
| Mezzion Pharma | 7.91B |